Overall survival was similar in women treated with fertility-sparing surgery and radical surgery.
-
-
ESMO 2020 — Is there a role for trabectedin in ovarian cancer progressing after platinum treatment? Prolonging the platinum-free interval using trabectedin after recurrence failed to improve overall survival compared to carboplatin.
-
An analysis of data from high-risk women referred to the Manchester Centre for Genomic Medicine with ovarian cancer.
-
High-grade ovarian cancer: gene signature may boost prognostication A 101-gene expression signature called OTTA-SPOT.
-
Serous ovarian cancer: binimetinib fails phase 3 KRAS mutation is associated with significant PFS improvement with binimetinib.
-
ESMO's first recommendations for multigene NGS in clinical daily practice Recommendations for routine use in NSCLC, cholangiocarcinoma, prostate, and ovarian cancers.
-
Recurrent ovarian cancer: rucaparib prolongs quality-adjusted survival Patients receiving rucaparib had longer time without clinically relevant symptoms.
-
Ovarian cancer: HIPEC with surgery improves survival Patients with complete surgery show 3-year OS benefit with HIPEC.
-
Although not meeting the primary endpoint, binimetinib should be considered a viable treatment for recurrent or persistent low-grade serous ovarian carcinomas.
-
ASCO guidelines: PARP inhibitors in ovarian cancer Guidelines pertain to PARP inhibitor-naive patients.
-
Advanced ovarian cancer: maintenance olaparib extends PFS in all subgroups Prespecified subgroup analyses of SOLO1 trial.
-
Recurrent ovarian cancer: bevacizumab-sorafenib combo misses mark Shows potential clinical activity in bevacizumab-naive patients in phase 2 trial.
-
Ovarian cancer: reduced hospital stay with enhanced postsurgery recovery program No increased complications in this comparison of enhanced recovery, conventional management.
-
European Society of Gynaecological Oncology and European Society for Paediatric Oncology joint guidelines.